US Stock MarketDetailed Quotes
ALMS Alumis
- 9.460
- +0.020+0.21%
Close Nov 22 16:00 ET
- 9.460
- 0.0000.00%
Post 16:02 ET
514.69MMarket Cap-2155P/E (TTM)
9.720High9.090Low120.50KVolume9.480Open9.440Pre Close1.14MTurnover0.68%Turnover RatioLossP/E (Static)54.41MShares13.53052wk High1.48P/B166.97MFloat Cap8.22552wk Low--Dividend TTM17.65MShs Float13.530Historical High--Div YieldTTM6.67%Amplitude8.225Historical Low9.456Avg Price1Lot Size
About Alumis Company
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.
Company Profile
SymbolALMS
Company NameAlumis
Listing DateJun 28, 2024
Issue Price16.00
Founded2021
CEOMr. Martin Babler
MarketNASDAQ
Employees109
Fiscal Year Ends12-31
Address280 East Grand Avenue
CitySan Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-650-231-6625
Websitehttp://www.alumis.com
Company Executives
- Name
- Position
- Salary
- Martin Babler
- Chairman of the Board, President and Chief Executive Officer
- 4.59M
- Dr. David M. Goldstein, PhD
- Chief Scientific Officer
- 1.04M
- Dr. Jorn Drappa, M.D.,PhD
- Chief Medical Officer
- --
- Mark Bradley
- Chief Development Officer
- --
- John R. Schroer
- Chief Financial Officer
- --
- Roy C. Hardiman
- Chief Business and Legal Officer
- 1.04M
- Derrick Richardson
- Senior Vice President, People and Culture
- --
- Dr. James B. Tananbaum,M.D.
- Independent Director
- --
- Dr. Alan B. Colowick, M.D.,M.P.H.
- Independent Director
- --
- Patrick C. Machado, J.D.
- Independent Director
- --
- Dr. Sapna Srivastava, PhD
- Independent Director
- --
- Dr. Zhengbin Yao, PhD
- Independent Director
- --
- Dr. Srinivas Akkaraju, M.D.,PhD
- Independent Director
- --
- Sara Klein
- General Counsel and Corporate Secretary
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
